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Abstract
Background: Myocardial scarring can be assessed by cardiac magnetic resonance imaging with late gadolinium
enhancement and by endomyocardial biopsy. However, accuracy of late gadolinium enhancement for predicting
microscopic myocardial scarring in biopsied specimens remains unknown in hypertrophic cardiomyopathy. We investigated
whether late gadolinium enhancement in the whole heart reflects microscopic myocardial scarring in the small biopsied
specimens in hypertrophic cardiomyopathy.
Methods and Results: Twenty-one consecutive patients with hypertrophic cardiomyopathy who were examined both by
cardiac magnetic resonance imaging and by endomyocardial biopsy were retrospectively studied. The right interventricular
septum was the target site for endomyocardial biopsy in all patients. Late gadolinium enhancement in the ventricular
septum had an excellent sensitivity (100%) with a low specificity (40%) for predicting microscopic myocardial scarring in
biopsied specimens. The sensitivity of late gadolinium enhancement in the whole heart remained 100% with a specificity of
27% for predicting microscopic myocardial scarring in biopsied specimens. Quantitative assessments of fibrosis revealed
that the extent of late gadolinium enhancement in the whole heart was the only independent variable related to the
microscopic collagen fraction in biopsied specimens (b = 0.59, 95% confident interval: 0.15 – 1.0, p = 0.012).
Conclusions: Although there was a compromise in the specificity, the sensitivity of late gadolinium enhancement was
excellent for prediction of microscopic myocardial scarring in hypertrophic cardiomyopathy. Moreover, the severity of late
gadolinium enhancement was independently associated with the quantitative collagen fraction in biopsied specimens in
hypertrophic cardiomyopathy. These findings indicate that late gadolinium enhancement can reflect both the presence and
the extent of microscopic myocardial scarring in the small biopsied specimens in hypertrophic cardiomyopathy.
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Introduction
Hypertrophic cardiomyopathy (HCM) is a primary cardiac
disorder characterized by myocardial hypertrophy in the absence
of other loading conditions, such as aortic stenosis or hypertension
[1]. Histopathological criteria for HCM include myocyte hyper-
trophy, myocyte disarray, nuclear hypertrophy, interstitial fibrosis
and myocardial scarring [2], which can be directly assessed by
endomyocardial biopsy [3,4]. However, potential pitfalls of
endomyocardial biopsy include sampling error [5–8]. Recent data
demonstrated that the sensitivity of endomyocardial biopsy for
diagnosing HCM is as high as 75% [2].
Myocardial scarring is defined as increased collagen with
evidence of cardiomyocyte loss [9]. In HCM patients, myocardial
scarring is patchy and often found in the ventricular septum [9–
12]. Determination of myocardial scarring is clinically important
because myocardial scarring is associated with unfavorable clinical
manifestations such as fatal ventricular arrhythmias and the
development of heart failure in HCM [13–16]. Cardiac magnetic
resonance imaging (CMR) with late gadolinium enhancement
(LGE) imaging has been established recently as the imaging
method for the assessment of myocardial scarring [5,13–16]. The
development of LGE-CMR techniques enables us to examine
diagnostic accuracy of LGE-CMR for determination of micro-
scopic myocardial scarring in biopsied specimens in HCM. The
aim of this study was to investigate whether LGE-CMR can be
used to predict myocardial scarring in small biopsied specimens in
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Twenty-three consecutive HCM patients who were examined
both by LGE-CMR and by endomyocardial biopsy at Kanazawa
University Hospital were retrospectively studied. HCM was
diagnosed by the presence of a non-dilated and hypertrophied
left ventricle on two-dimensional echocardiography (wall thickness
$ 13 mm) in the absence of another disease that could account for
the hypertrophy [17]. End-stage HCM was defined as a left
ventricular ejection fraction ,50% by two-dimensional echocar-
diography [12]. Two patients were excluded from the study due to
unsatisfactory biopsy samples (i.e., samples yielding only endocar-
dium). Thus, data from a total of 21 patients were included in the
analyses of this study. Written informed consent was obtained
from every patient before respective procedure (LGE-CMR or
endomyocardial biopsy). The study complies with the Declaration
of Helsinki. The study protocol was approved by the Bioethical
Committee on Medical Research, School of Medicine, Kanazawa
University.
Electrocardiography
A standard 12-lead ECG (0.5 to 150 Hz, 25 mm/sec, 10 mm/
mV) was recorded in the supine position during quiet respiration.
Pathological Q waves were defined as follows; Q wave.1/3 of the
ensuing R wave in depth and/or .40 msec in duration in at least
2 contiguous leads except aVR [18]. Negative T waves .10 mm
in depth in any leads were defined as giant negative T waves [18].
Absence of Q waves in leads I, aVL, V5 and V6 was defined as
absent Q waves in lateral leads [18].
Echocardiography
Standard M-mode and two-dimensional echocardiographic
studies were performed to identify and quantify morphological
features of the left ventricle in accordance with the guideline of the
American Society of Echocardiography [19–20].
Endomyocardial biopsy and histological assessments of
fibrosis
Selection of patients for endomyocardial biopsy was clinically
determined according to a scientific statement regarding the role
of endomyocardial biopsy in the management of cardiovascular
disease [7]. Myocardial biopsy samples were taken from the right
ventricular septal wall using a flexible bioptome [21]. No major
complications such as cardiac rupture, pericardial tamponade or
complete atrioventricular block occurred during endomyocardial
biopsy. Sections were stained with hematoxylin-eosin and Azan
dye and evaluated to identify interstitial and myocardial scarring.
Interstitial fibrosis was defined as increased interstitial collagen
without evidence of cardiomyocyte loss [9,22]. Myocardial
scarring was defined as increased interstitial collagen with evidence
of cardiomyocyte loss [9,22]. The presence of islands of surviving
cardiomyocyte among fibrotic tissues was considers as evidence of
cardiomyocyte loss [23]. Representative histopathological images
of interstitial fibrosis and myocardial scarring were shown in
Figures 1B and 1C–D, respectively. The collagen volume fraction
Figure 1. Qualitative and quantitative assessments of myocardial fibrosis in endomyocardial biopsy and LGE-CMR in the HCM
patients. (A–C) Typical histology from endomyocardial biopsy. Upper panels; no pathological fibrosis (A), increased interstitial fibrosis (B), and
severe myocardial scarring (C). Slides were stained with Azan dye. Interstitial fibrosis was defined as increased interstitial collagen without evidence of
cardiomyocyte loss [9,22]. Lower panels: areas of fibrosis visualized by ImageJ software. Fibrosis volume fraction determined by digital planimetry
was 2% (A), 15% (B) and 45% (C), respectively. Myocardial scarring was defined as increased interstitial collagen with evidence of cardiomyocyte loss
[9,22]. The presence of islands of surviving cardiomyocyte among fibrotic tissues was considers as evidence of cardiomyocyte loss [23]. (D) Islands of
surviving cardiomyocyte (arrows) among fibrotic tissues observed with high magnification of Image C. (E and F) Defining and quantifying LGE.
Representative HCM patients with no LGE (E) and with positive LGE (F). Areas of LGE (traced by yellow lines) were quantified by manual planimetry
and presented as percentage of left ventricular areas (traced by blue lines). Total of 6 short axes views were analyzed in each HCM patient. The LGE
volume fraction was 0% in Case D, and 16% in Case E. Scale bars represent 200 mm. CMR = cardiac magnetic resonance imaging, HCM =
hypertrophic cardiomyopathy, LGE = late gadolinium enhancement.
doi:10.1371/journal.pone.0101465.g001
LGE Predicts Microscopic Myocardial Scarring in HCM
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was manually quantified using ImageJ software by 2 experienced
investigators (T.K., Y.N.) who were blinded to the clinical
information of the patients. The percentage area of fibrosis in
each section was obtained by dividing the sum of the fibrotic areas
of the section by that of the total tissue area (Figures 1A–C) [24].
CMR Acquisition
CMR imaging was performed with a 1.5 Tesla scanner (GE).
Delayed-enhancement images for detection of fibrosis were
obtained 10 minutes after intravenous administration of gadolin-
ium–DTPA (0.2 mmol/kg) [25]. Total of 6 short axis images were
analyzed to qualify and quantify LGE. LGE was defined by a
signal intensity of . 6 standard deviations above normal
myocardium [26]. The LGE area was measured by manual
Table 1. Characteristics of the 21 patients with HCM.
N = 21
Age (years) 57.8 6 11.1
Male/Female, n 16 & 5
Phenotype
ASH, n (%) 14 (67)
Apical, n (%) 1 (5)
Diffuse, n (%) 3 (14)
End-stage HCM, n (%) 5 (24)
Echocardiogram
MWT (mm) 17.9 6 5.6
IVST (mm) 16.8 6 6.0
PWT (mm) 11.1 6 2.1
LVDD (mm) 50.0 6 11.0
LVEF (%) 61.2 6 19.2
LAD (mm) 45.6 6 7.4
Electrocardiogram
AF, n (%) 2 (9)
CRBBB, n (%) 4 (19)
CLBBB, n (%) 0 (0)
QRS axis (degree) 28.6 6 52.4
QRS width (msec) 115.3 6 20.2
QTc interval (msec) 440.6 6 35.9
SV1 + RV5 (mV) 4.0 6 2.1
Pathological Q waves, n (%) 3 (14)
Giant negative T waves, n (%) 5 (24)
Absent Q waves in lateral leads, n (%) 8 (38)
AF = atrial fibrillation; ASH = asymmetrical septal hypertrophy; CLBBB = complete left bundle branch block; CRBBB = complete right bundle branch block; HCM =
hypertrophic cardiomyopathy; IVST = intraventricular septal wall thickness; LAD = left atrial dimension; LVDD = left ventricular end-diastolic dimension; LVEF = left
ventricular ejection fraction; MWT = maximal wall thickness; PWT = posterior wall thickness.
doi:10.1371/journal.pone.0101465.t001
Table 2. Histological characteristics of fibrosis in biopsy specimens in the 21 patients with HCM.
N = 21
Fibrosis present, n (%) 17 (81)
Types of fibrosis, n (%)
Interstitial only 11 (52)
Scarring only 0 (0)
Interstitial and scarring 6 (29)
Total fibrosis fraction (%) 19.0 6 16.8
Interstitial fibrosis; increased interstitial collagen without evidence of myocyte loss. Myocardial scarring; increased interstitial collagen with evidence of myocyte loss
[9,22]. The presence of islands of surviving cardiomyocyte among fibrotic tissues was considers as evidence of cardiomyocyte loss [23]. HCM as in Table 1.
doi:10.1371/journal.pone.0101465.t002
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planimetry using ImageJ software (National Institutes of Health,
Bethesda, Maryland) in each short-axis image [27]. The area of
the left ventricle was determined by manually tracing epicardial
and endocardial borders in each short-axis image. The percentage
area of LGE was then calculated by dividing the sum of the LGE
areas by that of the total left ventricular area [27]. Data were
presented both as percentage of the left ventricular area and as a
binomial variable; positive/negative (Figures 1E and F). CMR
data were analyzed by 2 experienced investigators (E.M., Y.N.)
with consensus without knowledge of the clinical information of
the patients.
Statistical Analysis
Values are expressed as the mean 6 standard deviation.
Correlation was assessed by linear regression analysis and the
Pearson correlation coefficient. Unadjusted and multivariate-
adjusted linear regression analyses were used to assess the
associations between the clinical parameters and the microscopic
collagen fraction. First, each parameter was univariately analyzed
in the regression model using the percentage area of microscopic
fibrosis as the dependent variable (unadjusted model). Then,
significant variables in the unadjusted analysis were subjected to
the multivariate analysis together with age and gender (Multivar-
iate model). Sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) were defined as previously
reported [28]. P ,0.05 was considered statistically significant.
Results
Patients Characteristics
Baseline characteristics of the 21 patients with HCM are
summarized in Table 1. Of these 21 patients, 14 (67%) had
asymmetric septal hypertrophy, and 3 (15%) had the phenotype of
end-stage HCM with decreased left ventricular ejection fraction
(,50%). The average maximal left ventricle wall thickness was
17.9 6 5.6 mm. Pathological Q waves and giant negative T waves
were observed in 2 (14%) and 5 (24%) of the 21 patients,
respectively.
Qualitative and qualitative data of fibrosis by
endomyocardial biopsy and LGE-CMR
Qualitative assessments of myocardial fibrosis in biopsy
specimens revealed that interstitial fibrosis without myocardial
scarring was present in 11 (52%) of the 21 patients, and interstitial
fibrosis with myocardial scarring was present in 6 (29%) of them
(Table 2). The mean collagen volume fraction in myocardial
biopsy samples was 19.0 6 16.8%. The extent of fibrosis varied
from no pathological fibrosis to severe myocardial scarring
(Figures 1 A–C). LGE was present in 17 (81%) of the 21 patients
with HCM and was predominantly located in the anteroseptal
Table 3. Characteristics of LGE-CMR in the 21 patients with HCM.
N = 21
LGE present, n (%) 17 (81)







Patterns of LGE, n (%)
Patchy midwall 17 (81)




LGE volume fraction (%) 8.5 6 9.7
CMR = cardiac magnetic resonance imaging; LGE = late gadolinium enhancement. HCM as in Table 1.
doi:10.1371/journal.pone.0101465.t003
Figure 2. Representative patterns of LGE in the HCM patients.
(A) No LGE. (B) Patchy midwall LGE in the anterior wall. (C) Linear
midwall LGE in anteroseptal and lateral wall. (D) Extensive midwall and
subendocardial LGE in the diffuse left ventricle.
doi:10.1371/journal.pone.0101465.g002
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segments (Table 3). The mean extent of LGE in the left ventricle
was 8.5 6 9.7%. The patchy midwall pattern, linear midwall
pattern, and subendocardial pattern of LGE were observed in 17
(81%), 9 (43%), and 3 (14%) of the 21 HCM patients, respectively
(Table 3). Representative images of various patterns of LGE were
demonstrated in Figure 2.
Diagnostic values of LGE-CMR for predicting microscopic
myocardial scarring in biopsied specimens in HCM
We first investigated whether LGE in the ventricular septum
predicted microscopic myocardial scarring in small biopsied
specimens in the 21 HCM patients. For predicting microscopic
myocardial scarring, LGE showed an excellent sensitivity (100%);
all of the 6 patients who had microscopic myocardial scarring
showed LGE in the ventricular septum. In contrast, 6 (40%) of the
15 patients who did not have microscopic myocardial scarring
were negative for LGE in the ventricular septum. Thus, the
sensitivity, specificity, PPV, NPV and accuracy of LGE in the
ventricular septum for predicting microscopic myocardial scarring
were 100%, 40%, 40%, 100% and 57%, respectively (Table 4).
We then investigated the diagnostic values of LGE in the whole
heart for predicting microscopic myocardial scarring in biopsied
specimens in the 21 HCM patients. The sensitivity of LGE in the
whole heart remained 100%, but the specificity decreased (27%).
The sensitivity, specificity, PPV, NPV and accuracy were 100%,
27%, 35%, 100% and 48%, respectively (Table 4).
LGE in the ventricular septum showed poor diagnostic accuracy
for predicting microscopic interstitial fibrosis in the 21 HCM
patients; the sensitivity, specificity, PPV, NPV and accuracy were
76%, 50%, 87%, 33% and 29%, respectively (Table 4). Addition-
ally, the sensitivity, specificity, PPV, NPV and accuracy of LGE in
the whole heart for predicting microscopic interstitial fibrosis were
88%, 50%, 88%, 50% and 19%, respectively (Table 4).
The study population included 5 patients with end-stage HCM
(Table 1). Even when these 5 end-stage HCM patients were
excluded (n = 16), LGE showed similar diagnostic values for
detecting microscopic myocardial scarring or interstitial fibrosis
(Table 5); the sensitivity, specificity, PPV, NPV and accuracy of
LGE in the whole heart for predicting microscopic myocardial
scarring were 100%, 33%, 33%, 100% and 50%, respectively
(Table 5). Additionally, the sensitivity, specificity, PPV, NPV and
accuracy of LGE in the whole heart for predicting microscopic
interstitial fibrosis were 85%, 67%, 92%, 50% and 19%,
respectively in the 16 HCM patients (Table 5).
Relationships between the LGE fraction and the
microscopic collagen fraction
Since the results showed an excellent sensitivity of LGE in the
whole heart for predicting microscopic myocardial scarring in
biopsied specimens, we then asked whether or not the extent of
LGE in the whole heart predicted the microscopic collagen
fraction. Unadjusted regression analyses demonstrated a correla-
tion between the LGE fraction in the whole heart and the
microscopic collagen fraction in biopsied specimens (r = 0.51, p
= 0.019) (Figure 3A, Table 6). Multivariate adjusted regression
analyses revealed that the extent of LGE in the whole heart was
the independent variable related to the microscopic collagen
fraction in biopsied specimens, even after adjustments for clinical
cofounders (Table 6).
We next examined whether the LGE fraction correlated with
the microscopic collagen fraction even when the 5 end-stage HCM
patients were excluded from analyses. In the remaining 16 HCM
Table 4. Diagnostic values of LGE for detecting microscopic myocardial scarring or interstitial fibrosis in biopsied specimens in the
HCM patients (N = 21).
Sensitivity Specificity PPV NPV Accuracy
Detecting microscopic myocardial scarring
LGE in ventricular septum 100% 40% 40% 100% 57%
LGE in whole heart 100% 27% 35% 100% 48%
Detecting microscopic interstitial fibrosis
LGE in ventricular septum 76% 50% 87% 33% 29%
LGE in whole heart 88% 50% 88% 50% 19%
NPV = negative predictive value; PPV = positive predictive value. HCM as in Table 1.
doi:10.1371/journal.pone.0101465.t004
Table 5. Diagnostic values of LGE for detecting microscopic myocardial scarring or interstitial fibrosis in biopsied specimens in the
HCM patients with preserved systolic function (N = 16).
Sensitivity Specificity PPV NPV Accuracy
Detecting microscopic myocardial scarring
LGE in ventricular septum 100% 50% 40% 100% 63%
LGE in whole heart 100% 33% 33% 100% 50%
Detecting microscopic interstitial fibrosis
LGE in ventricular septum 69% 67% 90% 33% 31%
LGE in whole heart 85% 67% 92% 50% 19%
HCM as in Table 1. NPV and PPV as in Table 4.
doi:10.1371/journal.pone.0101465.t005
LGE Predicts Microscopic Myocardial Scarring in HCM
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patients with preserved left ventricular ejection fraction, a
correlation between the LGE fraction in the whole heart and
the microscopic collagen fraction in biopsied specimens was
observed (r = 0.62, p = 0.011) (Figure 3B).
Discussion
These data demonstrate that the sensitivity of LGE was
excellent for prediction of microscopic myocardial scarring in
HCM although there was a compromise with specificity.
Furthermore, the extent of LGE independently correlated with
the severity of microscopic collagen fraction in biopsied specimens
in HCM patients.
Diagnostic values of LGE for predicting microscopic
myocardial scarring in biopsied specimens in HCM
There is excellent agreement between the location of myocar-
dial scarring determined postmortem and the antemortem LGE
location on CMR in HCM [13]. However, it has been unknown
whether LGE predicts microscopic myocardial scarring in small
biopsied specimens in HCM. In this study, we demonstrated that
LGE had an excellent sensitivity (100%) for predicting microscopic
myocardial scarring in biopsied specimens both in the ventricular
septum and in the whole heart (Table 4). Thus, all of the HCM
patients with microscopic myocardial scarring showed LGE, as
shown in a representative case in Figure 4A. Despite the excellent
sensitivity, there was a compromise with the specificity. LGE was
present in most (73%) of the HCM patients who did not show
microscopic myocardial scarring, as shown in Figure 4B. The
Figure 3. Relationships between the microscopic fibrosis fraction and the LGE fraction in the HCM patients. (A) A fair correlation was
found between the LGE fraction and the total fibrosis fraction in biopsied specimens (N = 21). (B) To examine whether the LGE fraction correlated
with the microscopic collagen fraction in HCM with preserved LV systolic function, 5 end-stage HCM patients were excluded from analyses. In the
remaining 16 HCM patients, a correlation between the LGE fraction in the whole heart and the microscopic collagen fraction in biopsied specimens
was observed (r = 0.62, p = 0.011). Abbreviations as in Figure 1.
doi:10.1371/journal.pone.0101465.g003
Table 6. Predictors of the collagen fraction in biopsied specimens (unadjusted and multivariate-adjusted regression analyses).
Univariate Multivariate
b 95% CI P value b 95% CI P value
% LGE 0.51 0.092 – 0.92 0.019 0.59 0.15 – 1.0 0.012
QRS width 0.47 0.045 – 0.89 0.032 0.016 20.46 – 0.49 0.94
AF 20.42 20.85 – 0.018 0.059
Pathological Q 20.40 20.84 – 0.046 0.076
QTc interval 0.25 20.22 – 0.71 0.27
LVEF 20.24 20.71 – 0.23 0.29
Gender 20.21 20.26 – 0.67 0.37 0.5 20.018 – 1.0 0.06
SV1 + RV5 20.20 20.52 – 0.24 0.45
Age 20.1 20.58 – 0.38 0.66 20.31 20.78 – 0.16 0.18
QRS axis 20.045 20.52 – 0.44 0.85
LVDD 0.04 20.44 – 0.52 0.86
Absent Q in lateral leads 0.039 20.44 – 0.52 0.87
MWT 20.019 20.50 – 0.46 0.93
PWT 0.015 20.47 – 0.50 0.94
CI = confident interval. AF, EF, HCM, LGE, LVDD, MWT and PWT as in Tables 1 and 3.
doi:10.1371/journal.pone.0101465.t006
LGE Predicts Microscopic Myocardial Scarring in HCM
PLOS ONE | www.plosone.org 6 July 2014 | Volume 9 | Issue 7 | e101465
patchy nature of fibrosis in HCM [9–13] might contribute to the
low specificity of LGE for predicting microscopic myocardial
scarring in HCM. Furthermore, some controversies exist over the
correlations between LGE and myocardial fibrosis in biopsied
specimens, which could in part be explained by different biopsy
procedures and the specimen size in each study [6,8,29–31].
Nonetheless, given the excellent sensitivity and NPV of LGE for
predicting microscopic myocardial scarring, LGE-CMR may play
an important role in preventing unnecessary and invasive
endomyocardial biopsies in the clinical assessment of HCM.
Although recent data showed that the LGE fraction at the
myectomy site accurately reflected the histopathological fibrosis
fraction in large myectomy specimens from HCM patients [32], it
has been unclear whether the LGE fraction in the whole HCM
heart correlates with the fibrosis fraction in small biopsied
specimens. Our data demonstrated that the extent of LGE in
the whole heart could reflect the severity of microscopic collagen
fraction in HCM (Figure 3, Table 6). Together, these findings
indicate that qualitative and quantitative assessments of noninva-
sive LGE-CMR may be used to predict both the presence and the
severity of microscopic myocardial scarring in HCM. Because
myocardial scarring in the HCM heart has been associated with
heart failure, malignant ventricular arrhythmias and sudden
cardiac death [14–16], further studies are needed to clarify
whether LGE has different ability to predict the occurrence of
cardiac events compared to microscopic myocardial scarring in
HCM patients.
Limitations
One limitation of this study was the small sample size. Another
limitation is a selection bias regarding the severity of the disease
because this study population was enrolled in a tertiary referral
center. Specifically, a high prevalence (24%) of end-stage HCM
patients in the studied population might have affected the results.
Although correlations between LGE and microscopic fibrosis were
observed even when these end-stage HCM patients where
excluded from the analyses (Figure 3B, Table 5), our results may
not be applicable to all HCM patients.
Conclusions
Although there was a compromise in specificity, LGE showed
an excellent sensitivity for predicting microscopic myocardial
scarring in small biopsied specimens. Moreover, the quantitative
LGE fraction in the whole heart correlated with the severity of
microscopic collagen fraction in biopsied specimens in HCM.
These findings suggest that qualitative and quantitative assess-
ments of noninvasive LGE-CMR may be used to predict both the
presence and the severity of microscopic myocardial scarring in
HCM.
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